|
MechanismTXA2 synthase inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Oral cetylated fatty acid for the improvement of function, quality of life, and pain in patients with moderate to severe knee osteoarthritis
100 Clinical Results associated with Imagenetix, Inc.
0 Patents (Medical) associated with Imagenetix, Inc.
100 Deals associated with Imagenetix, Inc.
100 Translational Medicine associated with Imagenetix, Inc.